title: Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.
abstract: The hormonal milieu at time of tumor surgery seems to have a significant impact on survival in premenopausal breast cancer patients. Indeed, surgery performed during the follicular phase of the menstrual cycle was suggested to correlate with a poor prognosis. To investigate the relationship between prognosis and menstrual cycle at time of surgery, we analyzed the expression of some markers associated with tumor aggressiveness, such as the hormone receptors, HER2, p53, Bcl2, and cathepsin D in breast carcinomas obtained from 198 premenopausal women who underwent surgery during different phases of the menstrual cycle. HER2 overexpression was found to fluctuate in hormone receptor-positive tumors. In actual fact, 20% of the tumors removed during the follicular phase scored HER2-positive, versus 8% of those removed during the luteal phase. Similarly, a number of hormone receptor-positive tumor specimens, obtained from the same patients during follicular and luteal phases, were scored HER2-positive when the sample was removed during the follicular phase and HER2-negative when removed in the luteal phase. Southern blot analysis of the HER2 gene indicated that, in hormone receptor-positive cases, the overexpression of HER2 is often not associated with gene amplification. The finding that overexpression of the HER2 gene, associated with tumor aggressiveness, can fluctuate according to the hormonal milieu may explain the increased survival of patients operated during the luteal phase. It is also relevant to the selection and treatment of patients most likely to benefit from anti-HER2 antibody therapy.
authors.affiliation: Istituto Nazionale per lo Studio e la Cura dei Tumori, Institute of Pathology, and Institute of Anatomy, Faculty of Medicine, Milan University, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Balsari
authors.forename: P
authors.initials: P
authors.lastname: Casalini
authors.forename: E
authors.initials: E
authors.lastname: Tagliabue
authors.forename: M
authors.initials: M
authors.lastname: Greco
authors.forename: S
authors.initials: S
authors.lastname: Pilotti
authors.forename: R
authors.initials: R
authors.lastname: Agresti
authors.forename: R
authors.initials: R
authors.lastname: Giovanazzi
authors.forename: L
authors.initials: L
authors.lastname: Alasio
authors.forename: C
authors.initials: C
authors.lastname: Rumio
authors.forename: N
authors.initials: N
authors.lastname: Cascinelli
authors.forename: M I
authors.initials: MI
authors.lastname: Colnaghi
authors.forename: S
authors.initials: S
authors.lastname: Ménard
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008597:Menstrual Cycle; D017697:Premenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D011956:Receptors, Cell Surface / Q000096:biosynthesis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011956:Receptors, Cell Surface